Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Veterinary Research

Open Access

Establishment and application of a competitive enzyme-linked immunosorbent assay differentiating PCV2 antibodies from mixture of PCV1/PCV2 antibodies in pig sera

  • Shuizhong Han1,
  • Yan Xiao1,
  • Dingding Zheng1,
  • Yanli Gu1,
  • Yajie Xuan1,
  • Yudan Jin1,
  • Wenqiang Pang1,
  • Yuxin Huang1,
  • Xiangdong Li1,
  • Junhua Deng1Email author and
  • Kegong Tian1, 2Email author
Contributed equally
BMC Veterinary ResearchBMC series – open, inclusive and trusted201612:175

https://doi.org/10.1186/s12917-016-0802-9

Received: 26 April 2016

Accepted: 17 August 2016

Published: 26 August 2016

Abstract

Background

Porcine cirovirus type 1 (PCV1) and type 2 (PCV2) are circulating in Chinese pig herds and the infected pigs develop antibodies to both viruses. Current commercial available ELISA kits cannot differentiate PCV2-specific antibodies from the mixtures of PCV1 and PCV2 antibodies in PCV1/2-infected or PCV2-vaccinated pigs. Therefore, the need for developing PCV2-specific ELISA methods is urgent to evaluate PCV2 antibody level in exclusion of PCV1 antibody interference after PCV2 vaccination.

Results

Virus-like particles (VLPs) of PCV2 based on the recombinant Cap protein were expressed in Escherichia coli. A competing ELISA was established by using the VLPs as coating antigen and a PCV2-specific monoclonal antibody as the competing antibody. The competing ELISA was compared with the results obtained by using an immunoperoxidase monolayer assay on 160 serum samples. The sensitivity and specificity of this competing ELISA were determined as 96.5 and 96.0 %, at 2 standard deviation from the mean or 91.8 and 100 % at 3 standard deviations from the mean. Next, a serological survey of 1297 vaccinated serum samples collected from commercial pig herds in Beijing, Hunan and Henan provinces in China was conducted. The results showed that 85.9 % of sera having positive PCV2 antibodies.

Conclusions

The competing ELISA we developed in this study was both sensitive and specific to PCV2 and was suitable for large-scale PCV2 antibody monitoring in exclusion of PCV1 antibody interference after PCV2 vaccination.

Keywords

Porcine circovirus 2(PCV2)Recombinant cap proteinVirus-like particleCompetitive ELISA

Background

Porcine circovirus (PCV) was first identified as a noncytopathic contaminant of PK-15 cell, and subsequently classified in the family Circoviridae [1]. PCV is a spherical non-enveloped virus with a diameter of approximately 17 nm, and a single-stranded closed circular genomic DNA 1.7 kb in size [2]. There are two genotypes of PCV, namely PCV1 and PCV2. Serological analysis reveals that cross-reactivity exists between PCV1 and PCV2 [3]. PCV1 is widely known to be nonpathogenic agent, and no discernible pathogenic have been associated with PCV1 infection in swine [4]. Conversely, PCV2 is related to several diseases, such as postweaning multisystemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), porcine respiratory disease complex (PRDC), reproductive disorders, enteritis, and proliferative and necrotizing pneumonia (PNP), totally as porcine circovirus disease (PCVD) [5].

PCV2 genome contains two major open reading frames (ORFs): ORF1 and ORF2. ORF1 encodes the protein which involves in viral DNA replication, whereas ORF2 encodes an approximately 30 kDa immunogenic capsid (Cap) protein [6]. It was reported that the recombinant Cap protein could self-assemble to form virus-like particles expressed either in insect cells or Escherichia coli [6, 7]. The recombinant Cap protein reacted strongly with serum from PCV2-infected or PCV2-vaccinated pigs, which suggested that it was a good candidate antigen for the development of diagnostic assays [8, 9].

In order to detect PCV2 antibody in serum, the most common diagnostic methods include indirect fluorescent assay (IFA) and immunoperoxidase monolayer assay (IPMA) [10, 11]. However, these tests are not PCV2-specific due to the fact of antigenic cross-reactivity between PCV2 and PCV1. Meanwhile, these techniques are not only time-consuming and labor-intensive, but also require experienced technicians to judge the result arbitrarily. Compared with the current available methods, Enzyme-linked immunosorbent assay (ELISA) can be automated which decrease the potential bias and fit for mass detection. Several ELISA assays have been developed using the PCV2 virons or recombinant Cap protein expressed in insect cells [1215].

In present study, a competitive ELISA (cELISA), using virus-like particles (VLP) of PCV2 rCap protein as the coating antigen and PCV2-specific monoclonal antibody (MAb) as the detecting antibody, was established. The establishment of this cELISA will facilitate to simply detect PCV2-specific antibodies from swine serum samples without PCV1 antibody interference.

Methods

PCV2 antigen and monoclonal antibody preparation

VLPs formed by recombinant Cap protein were produced in E.coli BL21 (DE3) strain as previously described [16] and used as the coating antigen for cELISA. Briefly, the supernatant of cell lysates containing recombinant Cap (rCap) protein was precipitated by 60 % saturated ammonium sulfate and resuspended, followed by anion ion-exchange chromatographic purification. The purified recombinant PCV2 Cap proteins have been completely re-assembled into VLPs in a buffer of 50 mM Tris–HCl and 500 mM NaCl. 200 μl (0.4 μg/μl) recombinant PCV2 Cap protein plus equal volume of Freund’s complete adjuvant was used as an immunogen to inject each of five female Balb/c mice (purchased from Vital Rivea Experimental Animal Technology Ltd., Beijing) via intraperitoneal injection for Mab production. Three booster immunizations with same dose of antigen plus Freund’s incomplete adjuvant were conducted at two-week intervals. Three days after the final booster injection, the mice were euthanized and spleen cells were fused with SP2/0 cells using standard procedure [17]. The hybridoma cells were maintained in RPMI1640 medium (Gibco, USA) with 17 % fetal bovine serum (Hyclone, USA). The supernatant of the hybridoma cells were harvested and tested for antibodies to PCV2 and PCV1 by IPMA. The colony of 3H11 MAb reactive to PCV2 but not to PCV1 tested by IPMA was subcloned two times and selected for use in the cELISA. The MAbs were labeled with horseradish peroxidase (HRP) according to the conventional methods [18].

Serum samples

Five colostrum-deprived specific-pathogen-free piglets (Purchased from SPF Swine Breeding and Management Centre, Beijing) were intranasally inoculated with 105.0 TCID50 infective doses of PCV2 SH strain. Serum samples were collected 0, 7, 14, 21, 28, 35, and 42 days post-vaccination (dpi) and separated for serological testing by IPMA and cELISA. Serum samples collected at 0 dpi worked as negative controls. One hundred and sixty clinical serum samples stored at National Research Center for Veterinary Medicine were tested by IPMA for cELISA development.

In the retrospective serologic study, a total of 1297 field pig serum samples were collected by Veterinary Diagnostic Laboratory from Beijing (377 samples), Hunan (432 samples) and Henan (488 samples) provinces in China. The experiments were carried out under the consent of animal owners. The serum samples were tested by the cELISA established in this study.

Immunoperoxidase monolayer assay (IPMA)

IPMA was used to detect the presence of antibodies to PCV2. Briefly, the confluent monolayer of PKK cells (a PK-15 deprived cell line) infected with PCV2 SH (MOI=0.01) or free of PCV, were fixed in 80 % acetone for 30 min at 4 °C. The plates were stored at −20 °C after three times washing with PBS (0.01 mol/L, pH7.2). The MAb or serum samples were diluted 1:50 with PBS (0.01 mol/L, pH7.2), and added into the PCV2- and mock-infected PKK cells, respectively, 50 μl/well, and then incubated at 37 °C for 40 min. The anti-PCV polyclonal antiserum (VMRD, USA) and negative serum gained from colostrums-deprived piglets were respectively prepared as the positive and negative control. After three times washing, 50 μl of 1:200 dilution of HRP-conjugated goat anti-mouse or goat-pig IgG (Sigma, USA) was added and incubated at 37 °C for 30 min. After three times washing, 50 μl of the substrates 3-amino-9-ethylcarbazole was added and incubated for 30 min at room temperature. After three times washing, the 1:10 dilution hematoxylin was added. Twenty seconds later, the plates were washed with water and examined under an inverted light microscope.

Development of cELISA

Optimized dilution of PCV2 VLP antigen and horseradish peroxidase-conjugated PCV2-specific MAb were established by systematic checkerboard titrations. The polystyrene microliter ELISA plates were coated with 1.6 μg PCV2 VLP in phosphate buffer (0.02 mol/L, pH7.4) at 4 °C for 16 ~ 24 h. After three times washing, the plates were blocked with 200 μl of 20 % calf bovine serum in phosphate buffer (0.02 mol/L, pH7.4) for 2 h at 37 °C. After three times washing, 50 μl of the serum samples were added to each well, then 50 μl of 1:2000 dilution MAb 3H11 conjugated with HRP (Sigma, USA) were added to the wells except the blank well. The plates were incubated at 37 °C for 30 min. After five times washing, 100 μl of the substrate solution (0.2 mg/ml of TMB and 0.2 % H2O2 in 0.05 mol/L citrate buffer, pH4.6) was added and the colorimetric reaction was developed at 37 °C for 15 min. The reaction was stopped by adding 50 μl of 2 mol/L sulphuric acid. The optical density (OD) was measured at 450 nm. The controls included positive control (in triplicate), negative control (in triple) and one blank control. The OD450 of the samples were converted to a percent inhibition (PI) value using the following formulation: PI (%) = (OD450 value of negative value − OD450 value of sample)/OD450 value of negative value × 100 %.

Reproducibility, thermal stability and specificity of the cELISA

Inter-assay and intra-assay repeatability for the established cELISA was evaluated by testing the sixty filed sera. For the inter-assay repeatability, three replicates of each serum samples were detected by the same batch of pre-coated ELISA plates. For the intra-assay repeatability, each serum samples were detected by three batches of pre-coated ELISA plates. Mean PI value and coefficient of variation (CV) of three replications of each test were calculated.

Thermal stability for the established cELISA was evaluated by testing five filed serums using the plates stored at 4 and 37 °C for six days, respectively. The PI value of each serum detected with the plates stored at 37 °C for six days was compared with those had been stored at 4 °C. Statistical analysis of the PI value was carried out by Students test using the SPSS 19.0 software. The significance level was set at 0.05 (p < 0.05).

To explore the specificity, positive sera for PCV1, classical swine fever virus (CSFV), high pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV), porcine parvovirus (PPV), and porcine pseudorabies virus (PRV) were tested with the established cELISA.

Results

Sera from experimentally infected piglets

Standard PCV2-negative and positive serum samples were house-made by infecting pig with PCV2. Sera from these pigs sampled at 28, 35 and 42 day post-infection (dpi) were reactive with PCV2-infected cells by IPMA and were used as PCV2-postive serum samples. Sera at 0, 7, and 14 dpi were not reactive with PCV2 and were used as negative serum samples in this study. The positive sera had OD450 values < 0.719 when tested by cELISA established in this study with the inhibition in excess of 77.8 %. By contrast, the negative sera had OD450 values larger than 1.270 with inhibition less than 60.8 %.

Determination of the cut-off of cELISA by using clinical sera

A total of 160 field serum samples tested by IPMA were used to determine the cut-off value of established cELISA (Table 1). Among them, 75 samples were confirmed to be serological PCV2-negative by IPMA. These serum samples were tested by the established cELISA in this study. Distributions of the cELISA PI values showing the frequency of IPMA-positive and -negative samples are shown in Fig. 1. The average PI values (x-axis) of the 75 IPMA negative sera detected by cELISA were 34.4 % ± 12.0 % (mean ± SD). When 58.4 % (mean + 2SD) was used as the cutoff value for percentage inhibition, the sensitivity was 96.5 % and specificity was 96.0 %, giving a 95 % confidence. When the cutoff increased to 70.4 % (mean + 3SD), the sensitivity and specificity of the cELISA was 91.8 and 100 %, giving a 99 % confidence.
Table 1

Determination of sensitivity and specificity of the cELISA using cut-off values of the mean negative PI plus two SD or three SD

cELISA*

IPMA*

Positive

Negative

Total

Positive

82a

3a

85a

78b

0b

78b

Negative

3a

72a

75a

7b

75b

80b

Total

85

75

160

Note:*IPMA immunoperoxidase monolayer assay, cELISA competitive enzyme-linked immunosorbent assay

aComepetitive ELISA positive 58.4 % inhibition or greater

bComepetitive ELISA positive 70.4 % inhibition or greater

Fig. 1

Distribution of the cELISA PI values for detection of IPMA positive and negative pig sera. The horizontal bar shows the frequency of IPMA-positive and -negative samples and the vertical bar shows the inhibition values

Reproducibility, thermal stability and specificity of the cELISA

The reproducibility of the cELISA was determined by calculating the coefficient of variation (CV) of the PI values from field serum samples. The inter-assay CV of the 40 PCV2-positive serum samples ranged from 0.06 to 4.62 %, while the intra-assay CV of those same samples ranged from 0.16 to 7.46 % (Table 2). The inter-assay and intra-assay of the 20 negative samples also exhibited good repeatability, showing 2.2–14.8 % and 5.1–14.6 % respectively. These data showed that this assay was repeatable with low and acceptable variations.
Table 2

Coefficient values of the 60 field sera tested by the cELISA

Inhibition range(%)

No. of sera tested

CV range (%)

Inter-assay

Intra-assay

81–100

20

0.06–2.31

0.16–7.46

70–80

20

0.8–4.62

0.64–5.31

<60

20

2.2–14.8

5.1–14.6

The thermal stability assay was performed by comparing the PI values of 5 PCV2 positive serum samples on different ELISA plates which have been stored at 4 and 37 °C for six days. The results showed there was no significant difference (p = 0.107) existed between these two temperature conditions.

In addition, the cross-reactivity of the cELISA with several positive sera against CSFV, HP-PRRSV, PPV, PRV and PCV1 was also tested according to the cELISA procedures. The OD450 values of all these sera were in excess of 1.930 (PI ≤ 38.5 %) and were negative.

Serological survey of PCV2-vaccinated pigs using the established cELISA

The results for the 1297 field serum samples, collected from three provinces in China are shown in Table 3. Of these, 1106 samples were positive (85.3 %) and 191 samples (14.7 %) were negative for PCV2 antibodies. Regionally, the positive rate was 80.6 % (348/432) in Hunan province, 79.3 % (387/488) in Henan province and 98.4 % (371/377) in Beijing city.
Table 3

Prevalence of antibodies to PCV2 in pig sera collected from Henan, Hunan, and Beijing

Areas

Positive

Negative

Total

Positive rate

Beijing city

371

6

377

98.4 %

Hunan province

348

84

432

80.6 %

Henan province

387

101

488

79.3 %

Total

1106

191

1297

85.3 %

Discussion

PCV2 is currently circulating worldwide and leads to huge economic losses to swine industries. The commonly used and most effective strategy to control this disease is vaccination. The antibodies elicited by vaccination are mainly targeted to the PCV2 Cap protein, the sole and highly immunogenic structural protein of virus. Therefore, evaluation of PCV2 antibodies after virus infection or vaccination may reflect the herd infection status or the efficacy of vaccines. Currently, the common analytical methods developed for the qualitative and quantitative analysis of PCV2 antibodies in serum samples are IIF and IPMA. However, the antibodies detected by IIF and IPMA were not PCV2-specific due to the antigenic cross-reactivity between the Rep proteins encoded by PCV2 and PCV1 [19]. Therefore, development of specific and convenient methods for PCV2 antibody evaluation is more meaningful in PCV2 serological test.

It was previously reported that ELISA coated with the recombinant PCV2 Cap protein or peptide could be used for the specific detection of PCV2 antibody [8, 20]. Several indirect ELISA methods using the recombinant Cap protein have been developed for detecting the presence of PCV2 antibody in pig sera [1214]. However, the indirect ELISA has some limitations including the high level of false positives due to the complex components of serum samples such as Rheumatoid factor and antibodies specific for other animal serum components. Compared with indirect ELISA, cELISA have distinct advantages. First, the secondary antibody against the tested species is nonessential. Secondly, the nonspecific background caused by the tested sera could be lower by using the specific anti-PCV2 MAb. A cELISA have been previously established for the detection of PCV2 antibodies [15]. In their studies, live PCV2 virions from the cell cultures have been used as the coating antigen. The use of live virus has the issue of biosecurity and the production of live virus as antigen is laborious and time-consuming. Therefore, in our study, E. coli-originated PCV2 VLPs have been used as coating antigen with the advantages of intact antigenicity and easier preparation.

Besides the PCV2 VLPs used as coating antigen in this study, a PCV2-specific MAb was employed as a competitor with test sera. The MAb used in this assay is not reactive with PCV1 which exclude the inference of PCV1 antibodies that existed in the serum samples. Both the serum samples from experimental infected with PCV2 and from the clinical animals were used to establish the cELISA. The sensitivity and specificity of the cELISA was determined by detecting 160 field serums which have been confirmed IPMA. When the cutoff value of this cELISA was set to 58.4 % inhibition, three IPMA positive/cELISA negative serum samples were detected. These serum samples may contain antibodies to different stain of PCV2 that were reactive by IPMA but not with cELISA since a wide range of viral epitopes could be recognized by the polyclonal antibodies in IPMA. Three IPMA negative/cELISA positive samples were also detected. This discrepancy may be explained by the higher sensitivity of cELISA than IPMA. When the cutoff increased to 70.4 % inhibition, the IPMA negative/cELISA positive disappeared and the numbers of IPMA positive/cELISA negative serums increase to seven. Hence, the gray zone of the cELISA was set to be in the region of 58.4 to 70.4 %, and the samples should be retested when PI values fall into the range.

The established cELISA was next applied to do the PCV2 serological survey by using 1297 serum samples collected from three different provinces. The results of the survey reveals the PCV2 antibody positive rates ranged from 79.3 to 98.4 % which indicates the good herd immunity after vaccination.

Conclusions

To summarize, a cELISA was successfully established in this study to specifically detect PCV2 antibodies in exclusion of PCV1 antibody interference in serum samples. The specificity and convenience of this cELISA will be a useful tool to evaluate the strength of post-vaccination antibody response and monitor the efficacy of current vaccines.

Abbreviations

PCV2: 

Porcine cirovirus 2

PCV1: 

Porcine cirovirus 1

ORFs: 

Open reading frames

ELISA: 

Enzyme-linked immunosorbent assay

Cap: 

Capsid

IFA: 

Indirect fluorescent assay

IPMA: 

Immunoperoxidase monolayer assay

cELISA: 

Competitive enzyme-linked immunosorbent assay

VLP: 

Virus-like particles

MAb: 

Monoclonal antibody

E.coli

Escherichia coli

HRP: 

Horseradish peroxidase

TCID50

Tissue culture infective dose

Dpi: 

Days post-vaccination

PBS: 

Phosphate-buffered saline

OD: 

Optical density

PI: 

percent inhibition

iELISA: 

Indirect enzyme-linked immunosorbent assay

Declarations

Acknowledgments

We want to thank all staffs who got involved in animal experiments in this study at National Research Center for Veterinary Medicine.

Funding

This work was supported by grant from Applied Technology R&D Funding Program in Luoyang City (Grant no.1401082A), Major Science and Technology Program in Henan Province (Grant No.131100110200), Innovation Scientists and Technicians Troop Construction Projects of Henan Province (Grant No.142101510001), Talents Plan for Scientific and Technological Innovation in Henan Province (Grant No.144200510002), and Science and Technology Innovation team in Henan Province (Team No.C20130005).

Availability of data and materials

The data set(s) supporting the results of this article is included within the article.

Authors’ contributions

SH conducted ELISA validation, statistical analysis. YX and JD conducted ELISA establish and statistical analysis. DZ conducted the screen of the hybridoma cell. YG conducted the screen of the hybridoma cell. YX conducted ELISA validation and IPMA detection. YJ conducted the production of ascetic. WP and YH prepared PCV2 VLPs. XL and KT conducted the design of the study and draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The animal trial in this study was approved by the Animal Care and Ethics Committee of China National Research Center for Veterinary Medicine and conventional animal welfare regulations and standards were taken into account.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Research Center for Veterinary Medicine
(2)
College of Animal Science and Veterinary Medicine, Henan Agricultural University

References

  1. Tischer I, Rasch R, Tochtermann G. Characterization of papovavirus-and picornavirus-like particles in permanent pig kidney cell lines. Zentralbl Bakteriol Orig A. 1974;226(2):153–67.Google Scholar
  2. Tischer I, Gelderblom H, Vettermann W, Koch MA. A very small porcine virus with circular single-stranded DNA. Nature. 1982;295(5844):64–6.View ArticlePubMedGoogle Scholar
  3. Allan GM, McNeilly F, Kennedy S, Daft B, Clarke EG, Ellis JA, Haines DM, Meehan BM, Adair BM. Isolation of porcine circovirus-like viruses from pigs with a wasting disease in the USA and Europe. J Vet Diagn Invest. 1998;10(1):3–10.View ArticlePubMedGoogle Scholar
  4. Tischer I, Bode L, Peters D, Pociuli S, Germann B. Distribution of antibodies to porcine circovirus in swine populations of different breeding farms. Arch Virol. 1995;140(4):737–43.View ArticlePubMedGoogle Scholar
  5. Segales J, Allan GM, Domingo M. Porcine circovirus diseases. Anim Health Res Rev. 2005;6(2):119–42.View ArticlePubMedGoogle Scholar
  6. Nawagitgul P, Morozov I, Bolin SR, Harms PA, Sorden SD, Paul PS. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J Gen Virol. 2000;81(Pt 9):2281–7.View ArticlePubMedGoogle Scholar
  7. Yin S, Sun S, Yang S, Shang Y, Cai X, Liu X. Self-assembly of virus-like particles of porcine circovirus type 2 capsid protein expressed from Escherichia coli. Virol J. 2010;7:166.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Sun SQ, Guo HC, Sun DH, Yin SH, Shang YJ, Cai XP, Liu XT. Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2. Virol J. 2010;7:274.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Ge M, Luo W, Jiang D, Li R, Zhao W, Chen G, Yang X, Yu X. Development and application of a double-antigen sandwich enzyme-linked immunosorbent assay for detection of antibodies to porcine circovirus 2. Clin Vaccine Immunol. 2012;19(9):1480–6.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Allan GM, Mackie DP, McNair J, Adair BM, McNulty MS. Production, preliminary characterisation and applications of monoclonal antibodies to porcine circovirus. Vet Immunol Immunopathol. 1994;43(4):357–71.View ArticlePubMedGoogle Scholar
  11. Dulac GC, Afshar A. Porcine circovirus antigens in PK-15 cell line (ATCC CCL-33) and evidence of antibodies to circovirus in Canadian pigs. Can J Vet Res. 1989;53(4):431–3.PubMedPubMed CentralGoogle Scholar
  12. Blanchard P, Mahe D, Cariolet R, Truong C, Le Dimna M, Arnauld C, Rose N, Eveno E, Albina E, Madec F, et al. An ORF2 protein-based ELISA for porcine circovirus type 2 antibodies in post-weaning multisystemic wasting syndrome. Vet Microbiol. 2003;94(3):183–94.View ArticlePubMedGoogle Scholar
  13. Shang SB, Li YF, Guo JQ, Wang ZT, Chen QX, Shen HG, Zhou JY. Development and validation of a recombinant capsid protein-based ELISA for detection of antibody to porcine circovirus type 2. Res Vet Sci. 2008;84(1):150–7.View ArticlePubMedGoogle Scholar
  14. Nawagitgul P, Harms PA, Morozov I, Thacker BJ, Sorden SD, Lekcharoensuk C, Paul PS. Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV. Clin Diagn Lab Immunol. 2002;9(1):33–40.PubMedPubMed CentralGoogle Scholar
  15. Walker IW, Konoby CA, Jewhurst VA, McNair I, McNeilly F, Meehan BM, Cottrell TS, Ellis JA, Allan GM. Development and application of a competitive enzyme-linked immunosorbent assay for the detection of serum antibodies to porcine circovirus type 2. J Vet Diagn Invest. 2000;12(5):400–5.View ArticlePubMedGoogle Scholar
  16. Xi X, Mo X, Xiao Y, Yin B, Lv C, Wang Y, Sun Z, Yang Q, Yao Y, Xuan Y, et al. Production of Escherichia coli-based virus-like particle vaccine against porcine circovirus type 2 challenge in piglets: Structure characterization and protective efficacy validation. J Biotechnol. 2016;223:8–12.View ArticlePubMedGoogle Scholar
  17. Galfre G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 1981;73(Pt B):3–46.View ArticlePubMedGoogle Scholar
  18. Wilson MB, Nakane PK. Recent development in the periodate method of conjugating horseadish peroxidase (HRPO) to antibodies: In: Knapp W, Holubar K, Wick G, Eds. Immunofluorescence and Related Staining Techniques. Amsterdam:Elservier/North-Holland Biomedical Press, 1978:215–224.Google Scholar
  19. Rodriguez-Arrioja GM, Segales J, Balasch M, Rosell C, Quintant J, Folch JM, Plana-Duran J, Mankertz A, Domingo M. Serum antibodies to porcine circovirus type 1 and type 2 in pigs with and without PMWS. Vet Rec. 2000;146(26):762–4.View ArticlePubMedGoogle Scholar
  20. Mahe D, Blanchard P, Truong C, Arnauld C, Le Cann P, Cariolet R, Madec F, Albina E, Jestin A. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. J Gen Virol. 2000;81(Pt 7):1815–24.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement